Brussels | The european Commission has placed a large order of treatments remdesivir from the american laboratory Gilead, which will treat 30 000 patients in the EU, announced on Wednesday the institution.
The contract, in the amount of 63 million euros, it is possible to put the beginning of August at the disposal of the 27 member States and the United Kingdom doses of Veklury, trademark of the antiviral remdisivir, first medicine to be approved at the level of the EU for the treatment of the COVID-19.
The treatment is intended to approximately 30 000 patients with severe symptoms.
“This should help cover the needs for the next few months, while ensuring a fair distribution at EU level, based on an allocation key, and taking into account the opinions of the european Centre of prevention and control of diseases”, explains the Commission in a press release.
The eu executive is preparing a joint call for tenders for additional reserves of this drug, in order to cover needs from October onwards.
The remdesivir had received the authorisation of the placing on the european market conditional at the beginning of July, in a record time. The european medicines Agency recommends its use in adults and adolescents from 12 years of age with pneumonia and in need of extra oxygen.